US 3720760A
· Wide et al.
· 1973
[cited by applicant]
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 4526938A
· Churchill et al.
· 1985
[cited by applicant]
US 4880078A
· Inoue et al.
· 1989
[cited by applicant]
US 5128326A
· Balazs et al.
· 1992
[cited by applicant]
US 5290540A
· Prince et al.
· 1994
[cited by applicant]
US 5374548A
· Caras
· 1994
[cited by applicant]
US 5399331A
· Loughrey et al.
· 1995
[cited by applicant]
US 5416016A
· Low et al.
· 1995
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5641870A
· Rinderknecht et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5667425A
· Pineau et al.
· 1997
[cited by applicant]
US 5679377A
· Bernstein et al.
· 1997
[cited by applicant]
US 5714350A
· Co et al.
· 1998
[cited by applicant]
US 5855913A
· Hanes et al.
· 1999
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 5874064A
· Edwards et al.
· 1999
[cited by applicant]
US 5912015A
· Bernstein et al.
· 1999
[cited by applicant]
US 5916597A
· Lee et al.
· 1999
[cited by applicant]
US 5934272A
· Lloyd et al.
· 1999
[cited by applicant]
US 5985309A
· Edwards et al.
· 1999
[cited by applicant]
US 5985320A
· Edwards et al.
· 1999
[cited by applicant]
US 5989463A
· Tracy et al.
· 1999
[cited by applicant]
US 6019968A
· Platz et al.
· 2000
[cited by applicant]
US 6121022A
· Presta et al.
· 2000
[cited by applicant]
US 6165745A
· Ward et al.
· 2000
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6277375B1
· Ward
· 2001
[cited by applicant]
US 6316024B1
· Allen et al.
· 2001
[cited by applicant]
US 6350466B1
· Li et al.
· 2002
[cited by applicant]
US 6350861B1
· Co et al.
· 2002
[cited by applicant]
US 6703199B1
· Koide
· 2004
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 7786268B2
· Fischer
· 2010
[cited by examiner]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 9284378B2
· Hu
· 2016
[cited by examiner]
US 20100150918A1
· Kufer
· 2010
[cited by examiner]
CN 102786592A
· 2012
[cited by applicant]
CN 103588874A
· 2014
[cited by applicant]
CN 104487090A
· 2015
[cited by applicant]
EP 1176195B1
· 2013
[cited by applicant]
JP 2002502222
· 2002
[cited by applicant]
JP 2016504015
· 2016
[cited by applicant]
WO 9105548A1
· 1991
[cited by applicant]
WO 9219244A2
· 1992
[cited by applicant]
WO 9429351A2
· 1994
[cited by applicant]
WO 9620698A2
· 1996
[cited by applicant]
WO 9732572A2
· 1997
[cited by applicant]
WO 9744013A1
· 1997
[cited by applicant]
WO 9747653A1
· 1997
[cited by applicant]
WO 9831346A1
· 1998
[cited by applicant]
WO 9915154A1
· 1999
[cited by applicant]
WO 9920253A1
· 1999
[cited by applicant]
WO 9954342A1
· 1999
[cited by applicant]
WO 9966903A2
· 1999
[cited by applicant]
WO 0042072A2
· 2000
[cited by applicant]
WO 03035835A2
· 2003
[cited by applicant]
WO 2003105894A1
· 2003
[cited by applicant]
WO 2006121168A1
· 2006
[cited by applicant]
WO 2007005874A2
· 2007
[cited by applicant]
WO 2009101611A1
· 2009
[cited by applicant]
WO 2009114335A2
· 2009
[cited by applicant]
WO 2010027423A2
· 2010
[cited by applicant]
WO 2010027827A2
· 2010
[cited by applicant]
WO 2010077634A1
· 2010
[cited by applicant]
WO 2011066342A2
· 2011
[cited by applicant]
WO 2011066389A1
· 2011
[cited by applicant]
WO 2012065950A1
· 2012
[cited by applicant]
WO 2014048910A1
· 2014
[cited by applicant]
WO 2015026684A1
· 2015
[cited by applicant]
WO 2016057846A1
· 2016
[cited by applicant]
WO 2016061142A1
· 2016
[cited by applicant]
WO 2017059813
· 2017
[cited by applicant]
WO 2017060504
· 2017
[cited by applicant]
Langer, “Controlled release of macromolecules,” Chem. Tech. 12:98-105, 1982.
[cited by applicant]
Langer, “New methods of drug delivery,” Science 249:1527-1533, 1990).
[cited by applicant]
Langer, et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” J. Macromol. Sci. Rev. Macromol. Chem. 23:61, 1983.
[cited by applicant]
Lefranc, M.P., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Res., 29:207-209 (2001).
[cited by applicant]
Levy et al., “Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate,” Science 228:190, 1985.
[cited by applicant]
Lipsky et al., “Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis,” New Engl. J. Med. 343:1594-1602, 2000.
[cited by applicant]
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 262:732-745 (1996).
[cited by applicant]
Martin et al., “Modeling antibody hypervariable loops: A combined algorithm,” Proc. Natl. Acad. Sci. USA, 86:9268-9272 (1989).
[cited by applicant]
Martin et al., “Molecular modeling of antibody combining sites,,” Methods Enzymol., 203:121-153 (1991).
[cited by applicant]
Mattila et al., “Fidelity of DNA synthesis by the Thermococcus litoralis DNA polymerase—an extremely heat stable enzyme with proofreading activity,” Nucleic Acids Res. 19:4967, 1991.
[cited by applicant]
Meier et al., “Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection,” J. Virol Hepat. 2017; 24: 662-671.
[cited by applicant]
Milgrom et al., “Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody,” New Engl. J. Med. 341:1966-1973, 1999.
[cited by applicant]
Narang et al., “Improved phosphotriester method for the synthesis of gene fragments,” Meth. Enzymol. 68:90, 1979.
[cited by applicant]
Needleman and Wunsch, “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443 (1970).
[cited by applicant]
Ning et al., “Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel,” Radiotherapy & Oncology 39:179-189, 1996.
[cited by applicant]
O'Shannessy et al., “Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods,” Anal. Biochem 1993 212: 457…
[cited by applicant]
Ohtsuka et al., “An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions,” (1985) J. Biol. Chem. 260:2605-2608.
[cited by applicant]
Owais et al., “Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice,” (1995) Antimicrob. Agents Ch…
[cited by applicant]
Pearson, et al., “Improved tools for biological sequence comparison.,” Proc. Natl. Acad. Sci. USA 85:2444 (1988).
[cited by applicant]
Queen et al., “Cell-type specific regulation of a kappa immunoglobulin gene by promoter and enhancer elements,” Immunol. Rev. 89:49-68, 1986.
[cited by applicant]
Ranade, “Drug Delivery Systems. 1. Site-Specific Drug Delivery Using Liposomes as Carriers,” (1989) J. Clin. Pharmacol. 29:685.
[cited by applicant]
Rees et al., “Antibody combining sites: structure and prediction,” Oxford University Press, Oxford, 141-172 (1996).
[cited by applicant]
Rosenfeld et al., “In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium,” Cell 68:143, 1992.
[cited by applicant]
Rossolini et al., “Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information,” (1994) Mol. Cell. Probes 8:91-98).
[cited by applicant]
Ruiz et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Res., 28:219-221 (2000).
[cited by applicant]
Saudek et al.,“A preliminary trial of the programmable implantable medication system for insulin delivery,” N. Engl. J. Med. 321:574, 1989.
[cited by applicant]
Scharf et al., “Heat Stress Promoters and Transcription Factors,” Results Probl. Cell Differ. 20:125, 1994.
[cited by applicant]
Schreier et al., “Targeting of Liposomes to Cells Expressing CD4 Using Glycosylphosphatidylinositol-anchored gp120,” (1994) J. Biol. Chem. 269:9090-9098.
[cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J. Biol. Chem. 276:…
[cited by applicant]
Shields et al., “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity,”(2002) J. Biol. Chem. 277:26733-26740.
[cited by applicant]
Sidman et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers 22:547-556, 1983.
[cited by applicant]
Slamon et al., “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2,” New Engl. J. Med. 344:783-792, 2001.
[cited by applicant]
Smith and Waterman, “Comparison of biosequences,” Adv. Appl. Math. 2:482c (1981).
[cited by applicant]
Smith, A.E., “Viral vectors in gene therapy,” Annu. Rev. Microbiol. 49:807, 1995.
[cited by applicant]
Song et al.. “Antibody Mediated Lung Targeting of Long Circulating Emulsions,” PDA Journal of Pharmaceutical Science & Technology 50:372, 1996.
[cited by applicant]
Strohl, W., “Optimization of Fc-mediated effector functions of monoclonal antibodies,” 2009, Curr. Opin. Biotechnol. vol. 20(6):685-691.
[cited by applicant]
Thimme et al., “CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection,” J Virol. 2003; 77(1):68-76.
[cited by applicant]
Tropberger et al., “Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation,” Proc. Natl. Acad. Sci. U. S. A. 2015; 112: E5715-E5724.
[cited by applicant]
Umana et al., “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,” Nat. Biotech. 17:176-180, 1999.
[cited by applicant]
Umezawa et al., “Liposome targeting to mouse brain: Mannose as a recognition marker,” (1988) Biochem. Biophys. Res. Commun. 153:1038.
[cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Wieland et al., “Genomic analysis of the host response to hepatitis B virus infection,” Proc Natl Acad Sci U S A. 2004; 101(17):6669-74.
[cited by applicant]
Zapata et al., “Engineering linear F(ab')2 fragments for efficient production in
[cited by applicant]
Al-Lazikani et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,” J.Mol.Biol., 273:927-748 (1997).
[cited by applicant]
Zhang et al., “Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen,” Gut, 2016; (4) 65: 658-671.
[cited by applicant]
Altschul et al., “Basic local alignment search tool,” J. Mol. Biol. 215:403-410, 1990.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nuc. Acids Res. 25:3389-3402, 1977.
[cited by applicant]
Asabe, et al., “The size of the viral inoculum contributes to the outcome of hepatitis B virus infection,” J Virol. 2009; 83 (19):9652-62.
[cited by applicant]
Baert et al., “Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease,” New Engl. J. Med. 348:601-608, 2003.
[cited by applicant]
Batzer et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus,” Nucleic Acid Res. 19:5081 (1991).
[cited by applicant]
Baudino et al., “Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions,” J. Immunol. 181 : 6664-69 (2008).
[cited by applicant]
Beaucage et al., “Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis,” Tetra. Lett., 22:1859, 1981.
[cited by applicant]
Beniaminovitz et al., “Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody,” New Engl. J. Med. 342:613-619, 2000.
[cited by applicant]
Bird et al., “Single-chain antigen-binding proteins,” Science 242:423-426, 1988.
[cited by applicant]
Biswas et al., “Shift in the hepatitis B virus genotype distribution in the last decade among the HBV carriers from eastem India: possible effects on the disease status and HBV epidemiology,” Med. Virol. 2013; 85:1340-1…
[cited by applicant]
Bitter et al., “Expression and secretion vectors for yeast,” Meth. Enzymol., 153:516, 1987.
[cited by applicant]
Bloeman et al., “Adhesion molecules: a new target for immunoliposome-mediated drug delivery,” (1995) FEBS Lett. 357:140.
[cited by applicant]
Boni et al., “Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy,” Hepatology. 2001; 33(4):963-71.
[cited by applicant]
Briscoe et al., “Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes,” (1995) Am. J. Physiol., vol. 12(3), p. L374-L380).
[cited by applicant]
Brown et al., “Chemical synthesis and cloning of a tyrosine tRNA gene,” Meth. Enzymol. 68:109, 1979.
[cited by applicant]
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,” Surgery 88:507, 1980.
[cited by applicant]
Chisari, et al., “Hepatitis B virus immunopathogenesis,” Annu Rev Immunol. 1995; 13:29-60.
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, 342:877-883 (1989).
[cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments,” J. Mol. Biol., 227:799-817 (1992).
[cited by applicant]
Chothia, et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol., 196:901-917 (1987).
[cited by applicant]
Cleek et al., “Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application,” Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854, 1997.
[cited by applicant]
Dagan, et al., “Therapeutic antibodies against viral hepatitis,” Current Opinion in Molecular Therapeutics, 2003, 5 (2):148-155.
[cited by applicant]
DeRienzo et al., “Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation,” Pharmacotherapy 2000; 20:1175-8.
[cited by applicant]
During et al., “Controlled release of dopamine from a polymeric brain implant: In vivo characterization,” Ann. Neurol. 25:351, 1989.
[cited by applicant]
Meyers, et al., “Optimal alignments in linear space,” Bioinformatics, vol. 4, Issue 1, Mar. 1988, pp. 11-17.
[cited by applicant]
Eckert et al., “DNA polymerase fidelity and the polymerase chain reaction.,” PCR Methods and Applications 1:17, 1991.
[cited by applicant]
Ehrlich, et al., “Characterization of human monoclonal antibodies directed against hepatitis B surface antigen,” Hum. Antibod. Hybridomas, 1992, vol. 3, 6 pages.
[cited by applicant]
Elliot and O'Hare, “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,” Cell 88:223, 1997.
[cited by applicant]
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon y is mediated by a cell membrane receptor,” Proc. Natl. Acad. Sci. USA 82:3688-3692, 1985.
[cited by applicant]
Ghosh et al., “Natalizumab for Active Crohn's Disease,” New Engl. J. Med. 348:24-32, 2003.
[cited by applicant]
Goodson, in Medical Applications of Controlled Release, vol. 2, pp. 115-138, 1984.
[cited by applicant]
Guidotti et al., “Immunobiology and Pathogenesis of Viral Hepatitis,” Annu Rev Pathol. 2006; 1:23-61.
[cited by applicant]
Hamid, O. et al., “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma,” (2013) New England Journal of Medicine 369 (2): 134-44.
[cited by applicant]
Harrington et al., “Formation of de novo centromeres and construction of first-generation human artificial microchromosomes,” Nature Genetics, 15:345-355, 1997.
[cited by applicant]
Henikoff and Henikoff, “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992.
[cited by applicant]
Hollinger and Hudson, “Engineered antibody fragments and the rise of single domains,” Nature Biotechnology 23:1126-1136, 2005.
[cited by applicant]
Howard et al., “Acute subdural hematomas: an age-dependent clinical entity,” J. Neurosurg. 7 1:105, 1989.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study,” Proc. Natl. Acad. Sci. USA 77:4030-4034, 1980.
[cited by applicant]
Jefferis et al., “Human immunoglobulin allotypes,” MAbs. 1:332-338 (2009).
[cited by applicant]
Johnson et al., “Kabat Database and its applications: future directions,” Nucleic Acids Res., 29:205-206 (2001).
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences,” Proc. Natl. Acad. Sci. USA 90:5873-5787, 1993.
[cited by applicant]
Karlsson, et al., “Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors,” J. Immunol. Methods. 1997; 200: 121-133.
[cited by applicant]
Keinanen et al., “Biosynthetic lipid-tagging of antibodies,” (1994) FEBS Lett. 346:123.
[cited by applicant]
Killion et al., “Systemic Targeting of Liposome-Encapsulated Immunomodulators to Macrophages for Treatment of Cancer Metastasis,” (1994) Immunomethods 4:273.
[cited by applicant]
Knappik et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” J. Mol. Biol. 296:57-86, 2000.
[cited by applicant]
Lam et al., “Microencapsulation of recombinant humanized monoclonal antibody for local delivery,” Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760, 1997.
[cited by applicant]
Langer et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J. Biomed. Mater. Res. 15:267-277, 1981.
[cited by applicant]